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Article abs t racCWe traced the development of neurologic impairment in 207 homosexual men (123 human immuno- 
deficiency virus [HIV-positive and 84 HIV-negative controls) over 4.5 years of follow-up. We applied generalized esti- 
mating equations to logistic regression analyses with repeated measures to  examine the differences between HIV-posi- 
tive and HIV-negative subjects with respect to  the likelihood of developing six neurologic outcomes derived from a fac- 
tor analysis, significant neurologic impairment (modified Kurtzke disability score of 23), or significant neuropsycholog- 
ical impairment. We found that, over time, HIV-positive subjects were more likely to  develop clinically significant ex- 
trapyramidal signs and frontal release signs than HIV-negative subjects. Controlling for age or education, as CD4 
count declined, the odds of developing significant extrapyramidal signs, abnormalities in alternating movements, 
frontal release signs, and a Kurtzke score 23 increased. HIV-positive subjects were almost five times as likely (odds 
ratio [OR], 4.6; 95% CI, 1.6 to  13.4) as HIV-negative subjects to  stay the same or worsen neurologically on the next 
visit, and those with CD4 s200 were 4.8 times as likely (OR, 4.8; 95% CI, 2.2 to 10.7) to maintain or worsen neurologi- 
cally relative to those with higher CD4 counts. We conclude that neurologic impairment becomes increasingly apparent 
over time in HIV-infected men, especially in those with low CD4 counts. 
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Severe human immunodeficiency virus (HIV) infec- 
tion is characterized by a multitude of neurologic 
signs and symptoms including long tract and ex- 
trapyramidal signs, peripheral neuropathy, and de- 
mentia. In an  earlier cross-sectional assessment of 
207 homosexual men that included HIV-negative 
and  HIV-positive asymptomatic, mildly symp- 
tomatic, and moderately symptomatic patients, we 
found no difference in the frequency of neurologic 
signs and no decline in neurologic status with in- 
creasing medical symptomato1ogy.l The goal of the 
current analysis is to trace the development of neu- 
rologic signs and  symptoms in this same cohort 
over 4.5 years. 
Methods. Subjects. Two hundred seven homosexual men 
were recruited in late 1987 and early 1988 to participate 
in a 5-year follow-up study of HIV-infected subjects (n = 
123) and HIV-negative controls (n = 84). The majority of 
subjects were recruited via word of mouth, although two 
announcements were placed in “gay” monthly newslet- 
ters and one in a newspaper. Inclusion and exclusion cri- 
teria and screening procedures have been described else- 
where.2 All subjects were volunteers and gave informed 
consent. There were 168 subjects who entered the longi- 
tudinal phase of the study (113 HIV-positive and 55 HIV- 
negative) and were examined every 6 months for up to  
4.5 years. 
Assessments. At each visit, subjects received a stan- 
dardized medical examination for the purpose of staging, 
and neurologic, neuropsychological, psychiatric, and psy- 
chosexual assessments. Laboratory tests at each assess- 
ment included complete blood count and lymphocyte typ- 
ing. These assessments have been described previ- 
ously,1.2 but relevant assessments will be summarized 
below. Subjects received $10.00 per hour for their partici- 
pation in the study. This was used to  defray transporta- 
tion costs and maintain participation. 
Medical assessment. Physicians performed physical 
examinations targeted a t  HIV-related symptoms and 
signs. Subjects who met 1987 Centers for Disease Con- 
trol criteria for acquired immunodeficiency syndrome 
(AIDS)3 at baseline were not included in the study with 
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two exceptions. Because of the difficulty in clinically dis- 
tinguishing between oral and esophageal candidiasis on 
routine physical examination, we did not exclude men 
with esophageal candidiasis, which is on its own a crite- 
rion for AIDS. We also did not use the presence of cogni- 
tive impairment as an  exclusion criterion, because the 
purpose of the study was to assess nervous system ab- 
normalities in relatively medically asymptomatic individ- 
uals. 
Neurologic assessment. All neurologic examinations 
were performed by neurologists who were blind to the 
HIV status of the subjects. In the interests of maintain- 
ing blinding, the  neurologic examinations were per- 
formed prior to the elicitation of symptoms. Each neuro- 
logic sign was coded separately so that individual signs 
could be examined and factor scores could be created 
based on individual items. A standard neurologic exami- 
nation was performed. Items from the motor portion of 
the Unified Parkinson’s Disease Rating Scale4 were in- 
cluded to assess extrapyramidal function. Neurologic 
symptoms were rated using the structured interview cre- 
ated by Richard Price, MD.5 
Reliability of the neurologic examination was assessed 
by having three neurologists simultaneously rate signs 
and symptoms in 20 subjects. The neurologists took 
turns in performing the examination while the other two 
neurologists watched the examination and rated the in- 
dividual items. 
The neurologic data were summarized in two ways. 
First, an overall measure of neurologic disability was cal- 
culated for each subject, based on the Kurtzke Disability 
Status Scale for Multiple Sclerosis (Kurtzke score).6 The 
Kurtzke scale reflects both the number of areas of neuro- 
logic dysfunction (eg, pyramidal tract, cerebellum, brain- 
stem) and the severity of impairment. Derivation of the 
Kurtzke score has been previously described.l We chose a 
Kurtzke score of 3 or greater as indicative of a level of 
impairment that  most neurologists would reliably detect 
and consider clinically meaningful. A subject with a 
Kurtzke score of 3 would have moderate neurologic dis- 
ability but be fully ambulatory. 
The second way in  which the neurologic data were 
summarized was by performing a factor analysis on se- 
lected items of the neurologic examination. Creation of 
the neurologic factors has  been previously d e ~ c r i b e d . ~  
First, 76 individual items were reduced to nine summary 
variables. Each summary variable consisted of the sum 
of the individual items comprising it. These individual 
items were coded as 0 (sign absent) or 1 (sign present). 
For example, the extrapyramidal factor was composed of 
13 individual items, each coded as 0 or 1. Therefore, a 
score of 2 might indicate the presence of rigidity in two 
limbs but would not indicate severity. These summary 
variables were included in a principal components factor 
analysis with subsequent varimax rotation. Six factors 
were produced which proved stable over the 10 visits and 
represented major neurologic domains. Based on what 
the authors believed indicated clinical significance, the 
factors were dichotomized into high and low. For exam- 
ple, a score of 2 or greater on the extrapyramidal factor 
was considered “high” and anything less than two was 
considered “low.” Each individual’s score for extrapyram- 
idal status could then be classified as high or low. The 
six factors and the scores used to dichotomize them are 
shown in table 1. The creation ofneurologic factors facili- 
tated the exploration of the relationship between the 
neurologic signs and symptoms and other relevant co- 
variates. 
Table 1. Six neurologic factors and their 
components 
No. items 
Factor Cutpoint included Items 
Symptoms 23 11 All cognitive, motor, and 
behavioral items on Price 
questionnaire 
Alternating 21 8 Finger-tapping, opening 
pronation, supination, 
foot-tapping 
movements and closing hands, 
Frontal 23 7 Glabellar, snout, suck, and 
release palmomental reflexes; 
signs grasp 
Cranial 22 21 All cranial nerve signs 
Extra- 22 13 Rigidity in all limbs, 
nerve signs 
pyramidal bradykinesia, salivation, 
signs gait, hypomimia, speech, 
tremor (rest and action), 
posture 
Sensory 25 16 Pain and temperature, 
abnormalities vibration, position 
Each item is graded as 0 or 1, and maximum score equals number of 
items included. 
Neuropsychological assessment. The neuropsychologi- 
cal battery, also administered blind to HIV status, as- 
sessed a number of areas including memory, language, 
executive or “frontal lobe” function, attention, visuospa- 
tial function, and motor speed. The tests are described 
e1sewhere.l The neuropsychological examiners did not in- 
terview subjects about their symptoms or signs and were 
not aware of the medical or neurologic findings; there- 
fore, blinding could be maintained. In this analysis, per- 
formance on each test was compared with norms derived 
from populations of the same age and education. A global 
performance rating (GPR) was derived to summarize the 
neuropsychological performance at each visit. Perfor- 
mance was rated on a scale of 0 to 4, based on age- and 
education-appropriate norms as (0) normal, (1) border- 
line (at least 1 SD below the mean in two or more areas), 
(2) defective (at least 2 SD below the mean in one area), 
(3) defective (at  least 2 SD below the mean in  two or 
more areas), (4) defective (at least 2 SD below the mean 
in memory and two or more areas). 
Statistical analysis. Analyses of the longitudinal data 
were performed by applying generalized estimating 
equations (GEE) to logistic regression analyses with re- 
peated measures.8 The logistic analyses provide esti- 
mates of the odds of the occurrence of an  outcome depen- 
dent on the values of the covariates. The outcomes in- 
cluded the six neurologic factors, the modified Kurtzke 
score, and the GPR. All outcomes were dichotomized 
based on the presence or absence of clinically significant 
findings. For example, the extrapyramidal factor was di- 
chotomized based on the presence of two mild-to-moder- 
ate extrapyramidal signs (table 1). 
Using GEE, we examined the  differences between 
HIV-positive and HIV-negative subjects with respect to 
the likelihood of developing clinically significant findings 
for each outcome. Furthermore, with GEE, a statistically 
significant relationship between length of follow-up and 
an  outcome indicates a change (increase or decrease) in 
the odds of an outcome occurring over time. We also in- 
cluded the interaction of time and HIV status as a co- 
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Table 2. Baseline demographics 
, 
HIV+ (total) HIV- (total) HIV+ (deaths) HIV+ (LTFU) HIV- (LTFU) 
(n = 16) (n = 113) (n = 55) (n = 33) (n = 26) 
Age 38.4 (8.2) 38.6 (8.6) 40.4 (8.4) 36.1 (7.1) 39.0 (9.2) 
Education 16.0 (2.5) 16.7 (2.3) 16.1 (2.7) 15.7 (2.1) 16.9 (2.1) 
CD4 count 406.9 (220.1) 823.2 (272.5) 283.6 (192.7) 476.7 (210.3) 808.8 (312.0) 
Kurtzke score 1.2 (0.6) 1.1 (0.6) 1.3 (0.6) 1.1 (0.7) 0.9 (0.6) 
GPR 1.2 (1.1) 1.0 (1.2) 1.3 (1.1) 1.2 (1.3) 0.8 (1.0) 
Numbers in parentheses are SE values. 
LTFU Lost to follow-up. 
GPR Global performance rating. 
variate in some analyses. A significant interaction of HIV 
status and follow-up time would indicate that the odds of 
an outcome occurring over time differs as a function of 
HIV status. 
This statistical method takes into account the multi- 
ple visits per subject and the fact that the characteristics 
of a single individual over time are likely to be correlated 
with one another. The repeated measures for each sub- 
ject (up to 10 per variable) are treated as a cluster. A sec- 
ond advantage of GEE is that it takes into account the 
status or changing value of each covariate and outcome 
a t  each visit. 
A separate analysis was restricted to the HIV-positive 
subjects. The same outcome variables were examined 
with CD4, time, age, education, and GPR as covariates. 
A second type of analysis employed was a Markov re- 
gression model.g In this analysis, current status of out- 
come and risk factors were used to predict the probabil- 
ity of transition to specified outcomes on the next visit. 
Results. Demographics. One hundred sixty-eight 
subjects (1 13 HIV-positive and 55 HIV-negative) 
were included in the longitudinal follow-up. The 
baseline characteristics of the HIV-positive and 
HIV-negative subjects are presented in table 2. 
One of the HIV-negative subjects died and 16 were 
lost to follow-up (did not complete 10 visits). 
Among HIV-positive subjects, there were 33 deaths 
over 5 years, and 26 were lost to follow-up. Three of 
the HIV-positive subjects died after completing 
their 10th visit. Baseline CD4 counts of subjects 
who died differed significantly from those of HIV- 
negative subjects and from the other HIV-positive 
subjects (table 2). Other baseline characteristics 
did not differ between those who did and did not 
die. By visit 10, there were 57 HIV-positive sub- 
jects and 39 HIV-negative subjects. 
Prevalence of neurologic abnormalities. The 
prevalence of neurologic abnormalities at baseline 
in the 168 subjects is seen in table 3. HN-positive 
subjects had more symptoms than HIV-negative 
subjects at  baseline ( p  = 0.05). The prevalence of 
the other neurologic factors and the Kurtzke score 
was not significantly different in HIV-positive com- 
pared with HIV-negative subjects, but neither age 
nor education were controlled for in the analysis. 
To assess whether those who developed neurologic 
impairment (factor scores above cutpoints) during 
Table 3. Prevalence of neurologic outcomes at 
baseline 
I 
% HIV- % HIV+ 
(n = 55) (n = 113) 
Extrapyramidal signs 22 7.3 (4) 2.7 (3) 
Alternating movements tl 1.8 (1) 7.1 (8) 
Cranial nerve signs 22 12.7 (7) 8.0 (9) 
Sensory abnormalities 25 7.3 (4) 7.1 (8) 
Symptoms 23 14.6 (8)  29.2 (33)* 
Kurtzke score 23 1.8 (1) 2.7 (3) 
Numbers in parentheses represent number of subjects with each 
particular outcome. 
* p = 0.05. 
Frontal release signs 23 3.6 (2) 4.4 (5) 
I 
the course of follow-up were the most ill, the HIV- 
positive subjects were classified into four groups 
(asymptomatic, mild symptoms not consistent with 
AIDS-related complex [ARC], ARC, and AIDS) at 
the visit when they first developed a score above 
the cutpoint on an  individual neurologic factor. 
They were also classified by CD4 count at the first 
visit they demonstrated a neurologic factor score 
above cutpoint. As can be seen in table 4, neuro- 
logic endpoints were reached in  subjects in all 
stages of illness. Among those with a Kurtzke score 
23, most had a low CD4 count. In contrast, the ex- 
trapyramidal sign and frontal release sign out- 
comes were reached by patients with variable lev- 
els of immunosuppression. Because factor scores 
were dichotomized into high and low, it is unlikely 
that a few subjects with abrupt large changes ac- 
counted for the neurologic changes. More likely, 
many or most people experience slight and gradual 
change over time. 
Reliability of neurologic examination. Standard- 
ized neurologic examinations were performed in 20 
subjects by three independent examiners blind to 
HIV status. Reliability was in the good-to-excellent 
rangelo for examination of mentation and cranial 
nerve 'function and in the fair-to-good range for 
pyramidal tract signs, cerebellar signs, sensory ab- 
normalities, and extrapyramidal signs. Overall 
agreement (intraclass correlation) on the summary 
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Table 4. Severity of HIV infection at visit when 
neurologic outcome is first demonstrated 
No. 
subjects 
% Asymp- developing 
tomatic %Mild %ARC %AIDS outcome 






Frontal 22.2 (4) 23.2 (4) 36.9 (7) 16.7 (3) 16 
Kurtzke 0 ( 0 )  22.7 (5) 45.5 (10) 31.8 (7) 22 
%with No. subjects 
%with CD4 %with developing 
CD4 2600 200-500 CD4 1200 outcome 






l 8  I Frontal 0 (0) 66.7 (12) 33.3 (6) 
Kurtzke 9.1 (2) 22.7 (5) 68.2 (151 22 
Numbers in parentheses represent number of subjects with each particular out- 
come. 
neurologic measure, the modified Kurtzke score, 
was 0.89. 
Progression of neurologic factors and summary 
variables over time. HIV-positive versus HIV-nega- 
tive subjects. To determine whether the six neuro- 
logic factors (table 1) changed over time and 
whether the presence of HIV infection correlated 
with the severity of neurologic signs and symp- 
toms, we examined the cohort (HIV-positive and 
HIV-negative) over all visits. The six neurologic 
factors (table 11, the neurologic summary score 
(Kurtzke score), and the neuropsychological sum- 
mary variable (GPR) were dichotomized into high 
and low severity and were considered as outcome 
variables. HIV status, time from first visit for the 
HIV-negative and HIV-positive subjects separately, 
and the interaction of time by HIV status were in- 
cluded as covariates. By GEE (table 5, column l), 
at every visit HIV-positive subjects were more 
likely to have more symptoms (cognitive, motor, 
and mood complaints) and have a higher Kurtzke 
score (23) than HIV-negative subjects. The odds per 
year of having clinically meaningful symptoms and 
frontal release signs significantly decreased over 
time in the HIV-negative group. The odds of devel- 
oping extrapyramidal signs increased over time for 
the HIV-positive subjects. The odds of developing 
global neuropsychological impairment (GPR 23) de- 
creased in both HIV-negative and HIV-positive 
subjects over time. In contrast, with successive vis- 
its, impairment in alternating movements, sensory 
impairment, and a Kurtzke score 23 were' more 
likely to be present in both groups. There was a sig- 
nificant time-by-HIV interaction for the symptoms, 
extrapyramidal signs, and the frontal factors. This 
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Table 5. Odds ratios for the development of 
neurologic outcomes: HIV+ and HIV- subjects 
Outcome H N  status' 
variables (HIV+/HIV-) Time (HIV-) Time (HlV+) HlV by timet 
Extra- 0.4 (0.2-1.11 








Frontal 0.8 (0.2-2.7) 
Alternating 1.1 (0.6-1.9) 
Cranial 0.6 (0.4-1.1) 
Sensory 1.2 (0.7-2.0) 
Symptoms 2.1 (1.0-4.1)t 
Kurtzke 5.3 i1.6-17.5)$ 










2.0 (1.6-2.4)t 1.6 (1.1-2.1)t 




1.0 (0.9-1.1) 1.3 i1.0-1.6)t 
1.4 i1.1-1.7)$ 
0.6 (0.6-0.7)$ 
Odds ratios are per year. 
Numbers in parentheses are 95% confidence intervals. 
* Odds of H N +  compared with HIV- for developing neurologic outcomes at 
each visit. 
t A significant interaction indicates that the odds of an outcome occurring over 
time differs as a function of being HIV+ compared with being H N - .  HIV+ 
subjects were more likely to develop extrapyramidal signs, frontal release 
signs, and symptoms when followed longitudinally. 
t p  < 0.05. 
Table 6. Odds ratios for the development of 
neurologic outcomes: HIV+ subjects only 
I 
Outcome Baseline Education 






























Numbers in parentheses are 95% confidence intervals. 









suggests that  when followed longitudinally, the 
HIV-positive subjects were more likely to  develop 
clinically significant extrapyramidal signs, frontal 
release signs, and cognitive, motor, and mood 
symptoms than the HIV-negative subjects. 
HIV-positive only. GEE analysis was then re- 
stricted to the HIV-positive subjects (table 6). First, 
the effects of follow-up time, age at baseline, and 
education on the outcome variables (six neurologic 
factors, Kurtzke score, and GPR) were examined. 
The odds of developing a clinically significant level 
of extrapyramidal signs, sensory abnormalities, or 
Table 7. Odds ratios for the development of 
neurologic outcomes: HIV+ sub.iects only 
Outcome 
variables CD4 <200 200 < CD4 < 600 GPR 






Alternating 4.3 (1.9-9.7)* 2.9 (1.3-6.3P 4.9 (2.2-11.2)* 
Cranial 1.5 (0.6-3.4) 0.8 (0.4-1.8) 2.2 (0.9-5.5) 
Kurtzke 19.2 (2.6-141.3)* 4.8 (0.6-36.2) 2.2 (0.7-6.7) 





Sensory 1.5 (0.8-2.9) 0.8 (0.4-1.5) 1.2 (0.6-2.61 
Symptoms 1.0 (0.6-1.5) 0.8 (0.5-1.1) 1.5 (1.0-2.5) 
Kurtzke 
GPR 0.9 (0.4-1.91 0.7 (0.4-1.2) 2.7 (1.1-6.6P 
Numbers in parentheses are 95% confidence intervals 











Kurtzke score 23 increased over time, while the 
odds of developing significant neuropsychological 
impairment (GPR 23) decreased over time. Base- 
line age was associated with extrapyramidal signs, 
alternating movements, cranial nerve signs, and 
high level of neurologic disability (Kurtzke score 
231, indicating that older men tended to have more 
impairment on these outcomes than younger men. 
The odds of developing clinically significant frontal 
release signs or sensory abnormalities were in- 
creased in those subjects with lower education. 
A model was then constructed with GPR, CD4, 
and age or education as covariates, and the six neu- 
rologic outcome variables were dichotomized as de- 
scribed above. Adjusting for the effects of age or ed- 
ucation, the odds of developing alternating move- 
ment abnormalities, frontal release signs, sensory 
abnormalities, or a Kurtzke score 23 increased with 
declining CD4 count. Impaired cognitive status 
(GPR 23) increased the odds of having impairment 
in alternating movements. 
CD4 was then categorized as 1200, between 200 
and 500, or 2500. CD4 2500 was then considered as 
a reference group, instead of being treated as a con- 
tinuous variable (table 7); When CD4 was stratified 
as 1200 or 200 through 500, the odds of developing 
clinically significant extrapyramidal signs, alter- 
nating movements, and frontal release signs and a 
Kurtzke score 23 was higher for those with CD4 
1200 than for those with a CD4 2500. The odds of 
developing significant extrapyramidal signs, alter- 
nating movements, and frontal release signs were 
also increased for those in the 200 to 500 range 
compared to those with CD4 2500 (table 7). 
Lastly, GPR 23 was treated as an outcome (table 
7). The relationship between CD4 count, stratified 
as above, Kurtzke score, and time and the develop- 
ment of clinically significant cognitive impairment 
was examined. Among the HIV-positive subjects 
there was no relationship between CD4 and GPR, 
when adjusted for Kurtzke score. The odds of devel- 
oping cognitive impairment (GPR 23) increased 
with greater neurologic disability, as measured by 
the Kurtzke. The odds of developing clinically sig- 
nificant cognitive impairment decreased over time. 
Transitional probabilities. A Markov regression 
model was used to determine which factors were 
important in the transition or maintenance of a 
moderate level of neurologic impairment (defined 
as a score of 3 or greater on the Kurtzke disability 
status score). From the previous analysis, we know 
that the odds of having a Kurtzke score of 3 or 
greater increased with age, with HIV-positive sta- 
tus, and with lower CD4 counts. 
We investigated the effect of these covariates on 
the transition probability of developing a Kurtzke 
score 23. When the entire cohort was examined, age 
and HIV status were independent predictors of tran- 
sition to Kurtzke 23 on the next visit. Given age and 
Kurtzke score measured on a visit, the odds ratio of 
maintaining or developing a higher Kurtzke score 
(23) on the next visit in the HIV-positive group rela- 
tive to the HIV-negative group was 4.6 (95% CI, 1.6 
to  13.4). Given current age and Kurtzke score, the 
odds ratio for maintaining or developing a higher 
Kurtzke score on the next visit in HIV-positive pa- 
tients with CD4 <200 relative to those with higher 
CD4 counts was 4.8 (95% CI, 2.2 to 10.7). 
From this set of analyses, we can conclude that 
over time, HIV-positive subjects are more likely to 
develop clinically significant extrapyramidal signs 
and frontal release signs than HIV-negative sub- 
jects. Controlling for the effects of age, since neuro- 
logic impairment may be more common in older 
subjects, the odds of developing significant ex- 
trapyramidal signs, abnormalities in alternating 
movements, and  global neurologic disability 
(Kurtzke score 23) increase as CD4 declines. Con- 
trolling for the effects of education, the likelihood of 
developing frontal release signs also increases as 
CD4 declines. The odds of having clinically signifi- 
cant abnormalities in alternating movements is in- 
creased in subjects with severe cognitive impair- 
ment (GPR 23). Impairment in these neurologic do- 
mains is apparent in both those with CD4 counts 
1200 and those with counts between 200 and 500. 
In summary, those subjects with CD4 counts 5200 
were more likely to develop significant neurologic 
disability. Subjects with greater neurologic disabil- 
ity had a higher probability of developing signifi- 
cant cognitive impairment. No relationship be- 
tween low CD4 count and cognitive impairment 
was seen, after adjustment for neurologic impair- 
ment (Kurtzke score). 
Discussion. We have shown that neurologic signs, 
particularly abnormalities of rapid alternating 
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movements, frontal release signs, and extrapyrami- 
dal signs, are present in mildly to  moderately im- 
munologically compromised patients and that they 
are more likely to develop over time. This may re- 
flect early involvement of subcortical structures as 
demonstrated by PET,ll SPECT,12 and MR spec- 
tro~copy.'~ This is the first systematic longitudinal 
follow-up of neurologic impairment in HIV infec- 
tion. 
There are several unique aspects to this study. 
I n  contrast  to t he  Multicenter AIDS Cohort 
Study,14 rather than performing a screening assess- 
ment for neurologic impairment and then examin- 
ing only those meeting screening criteria, all sub- 
jects received detailed, reliable, standardized as- 
sessments at each visit. This allowed the detection 
of subtle neurologic impairment that although not 
functionally disabling, demonstrated nervous sys- 
tem involvement prior to the development of severe 
immunologic compromise. 
The factor analysis allowed an exploration of im- 
pairment in specific stable neurologic domains in 
relation to immunologic and neuropsychological 
measures. It is extremely unlikely that the increas- 
ing neurologic impairment is accounted for by a few 
people with abrupt, large changes. Dichotomizing 
the items that comprised each of the neurologic fac- 
tors into present or absent meant that, for exam- 
ple, a subject with severe rigidity in one limb re- 
ceived the same score as someone with mild rigid- 
ity. In addition, subjects with varying severity of 
HIV infection and not exclusively those with CD4 
count below 200 developed the neurologic outcomes 
(tables 3 and 4). Even after controlling for age or 
education using GEE, the odds of developing ex- 
trapyramidal signs, alternating movement abnor- 
malities, and frontal release signs were increased 
even in those subjects with CD4 counts in the 200 
to 500 range, compared with those subjects with 
CD4 over 500 (table 7). 
The findings here corroborate and extend earlier 
cross-sectional descriptions of neurologic impair- 
ment in subjects with AIDS.16-17 Frontal release 
signs and abnormalities in rapid alternating move- 
ments and extrapyramidal signs were common, al- 
though abnormalities in sensation were most com- 
mon. 
There are several limitations to this study. Al- 
though we have documented that neurologic im- 
pairment occurs at  all stages of HIV infection, we 
could not determine whether those who are either 
immunologically or cognitively more impaired 
gradually worsen neurologically or whether there 
is a sudden decline in neurologic function when a 
certain immunologic status is attained. The analy- 
ses reported here do not adequately capture the 
rate of change of HIV-positive subjects relative to 
HIV-negative subjects. For example, the learning 
effect apparent in the improvement in GPR in both 
groups is less robust in the HIV-positive group sug- 
gesting that the effects of HIV may be mediating 
this relative lack of improvement.ls 
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This study primarily describes mild-to-moderate 
neurologic impairment associated with HIV infec- 
tion. The study was designed to describe the rela- 
tionship between neurologic, neuropsychological, 
and medical findings early in the course of HIV in- 
fection. Few subjects reached the endpoints of se- 
vere neurologic impairment over the 4.5 years. The 
differences detected between HIV-positive and 
-negative men may be underestimated because 
HIV-positive subjects were often not examined 
when they became extremely ill. Only subjects who 
were ambulatory and able to  come to the center 
were examined neurologically and neuropsychologi- 
cally, although phone contact was maintained 
throughout the study. Of the 33 HIV-positive pa- 
tients who died, the average time from their last 
visit until death was about 8 months. This suggests 
that important neurologic outcomes may not have 
been recorded. It also means that factors such as 
opportunistic infections may not have influenced 
neurologic and neuropsychological performance to 
the extent that they might have, had this been a 
hospital-based cohort. For example, among 14 sub- 
jects who developed Pneumocystis carinii pneumo- 
nia, only two developed a Kurtzke score of 3 or 
above. This may also explain why among the HIV- 
positive subjects global cognitive function appeared 
to improve over time. There may have been differ- 
ential loss to follow-up of the most cognitively im- 
paired individuals. 
We have documented that, over time, HIV-posi- 
tive subjects are more likely than HIV-negative 
subjects to develop neurologic disability and that. 
there are specific neurologic signs (extrapyramidal 
and frontal release) that are more likely to develop 
in HIV-positive subjects over time compared with 
HIV-negative subjects, particularly those who are 
immunosuppressed. Detection of these early signs 
of impairment may be important in targeting those 
at risk for severe neurologic impairment. 
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after progression to AIDS: 
A longitudinal study from 
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Article abstrac W b j e c t i u e :  To describe changes in cognitive functioning before and after development of an acquired im- 
mune deficiency syndrome (AIDS)-defining illness or CD4+ lymphocyte count <200/mm3 in participants in the Multicenter 
AIDS Cohort Study. Methods: The study population included participants who either were diagnosed with an AIDS-defining 
illness (n = 52) or had at least one measurement of CD4+ count <200/mm3 (n = 57) and who had at least four neuropsycho- 
logical (NP) evaluations, two or more before and two or more after the AIDS diagnosis. A group of subjects with clinical di- 
agnosis of dementia (n = 29) was also included for comparison. The NP test battery included measures of attention, memory, 
constructional abilities, and psychomotor speed. Longitudinal data analysis, using the generalized estimating equation, was 
performed separately for each NP measure. Time was measured in months from the date of clinical AIDS or CD4+ 
<200/mm3. Results: Before AIDS, the dementia group showed significant decline (slope different from zero) only on mea- 
sures of psychomotor speed. For all other measures, there was no evidence of decline in performance before AIDS for the 
other groups. ARer development of AIDS, the group with clinical AIDS showed significant decline on psychomotor speed but 
none on the other cognitive measures. The group with CD4+ <200/mm3 did not show significant decline on any of the cogni- 
tive measures after AIDS. As expected, the dementia group showed significant decline on all measures. Sensory neuropathy 
was associated with a significant decline in performance on measures of psychomotor speed after AIDS. Antiretroviral ther- 
apy was not associated with any measurable changes in NP performance. Conclusion: These results are consistent with pre- 
vious findings showing no significant decline in cognitive functions before AIDS, unless overt dementia is present, and no 
decline in immunosuppressed subjects who have had no AIDS-defining illness. By contrast, in subjects who have developed 
clinical AIDS, there is mild decline in fine motor skills but no significant change in other cognitive domains. 
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Cognitive impairment is a well-recognized compli- 
cation of human immunodeficiency virus (HIV) in- 
fection. In its most severe form, this cognitive im- 
pairment manifests itself as a dementia syndrome 
with symptoms severe enough to influence activi- 
ties of daily living. The incidence of HIV-1 demen- 
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